In mouse models of IRI, sustained HIF-1α activation is associated with severe AKI and fibrosis, whereas administration of the HIF-1α inhibitor PX-478 ameliorates the transition from AKI to chronic kidney disease (CKD) (Li et al., 2021a). The gene discussed is HIF1A; the disease is acute kidney injury.